beta-lactams has been researched along with ppi-0903 in 15 studies
| Studies (beta-lactams) | Trials (beta-lactams) | Recent Studies (post-2010) (beta-lactams) | Studies (ppi-0903) | Trials (ppi-0903) | Recent Studies (post-2010) (ppi-0903) |
|---|---|---|---|---|---|
| 7,579 | 179 | 3,395 | 519 | 39 | 451 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Fritsche, TR; Jones, RN; Sader, HS | 1 |
| Appelbaum, PC; Kosowska-Shick, K; McGhee, PL | 1 |
| Dien Bard, J; Gold, HS; Hindler, JA; Limbago, B | 1 |
| Fernandez, R; Paz, LI; Rosato, AE; Rosato, RR | 1 |
| Abdelhamed, AM; Bajaksouzian, S; Bonomo, RA; Foster, AN; Gatta, JA; Jacobs, MR; Nichols, WW; Papp-Wallace, KM; Testa, R; Winkler, ML | 1 |
| Barber, KE; Raut, A; Rybak, MJ; Smith, JR | 1 |
| Nord, CE; Panagiotidis, G; Rashid, MU; Rosenborg, S; Söderberg-Löfdal, K; Weintraub, A | 1 |
| Raut, A; Rybak, MJ; Smith, JR; Yim, J | 1 |
| Chambers, HF; Chan, LC; Chatterjee, SS; Chiu, CY; Greninger, AL; Hamilton, SM | 1 |
| Cavaco-Silva, P; Matias, CS; Melo-Cristino, J; Mendes, JJ; Mottola, C; Oliveira, M; Tavares, L | 1 |
| Rybak, MJ; Tran, N | 1 |
| Arias, CA; Dinh, AQ; Kebriaei, R; Khan, A; Murray, BE; Rice, SA; Rybak, MJ; Singh, KV; Stamper, KC; Tran, TT | 1 |
| Bassetti, M; Giacobbe, DR; Pelosi, P; Robba, C; Vena, A | 1 |
| De Puysseleyr, L; Ebo, DG; Elst, J; Faber, MA; Hagendorens, MM; Mertens, CM; Romano, A; Sabato, V; van der Poorten, MM | 1 |
| Gutheil, WG; Sharma, AD | 1 |
1 review(s) available for beta-lactams and ppi-0903
| Article | Year |
|---|---|
Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftaroline; Ceftazidime; Cephalosporins; Cyclooctanes; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Public Health; Sepsis; Tazobactam | 2020 |
1 trial(s) available for beta-lactams and ppi-0903
| Article | Year |
|---|---|
Ecological Effect of Ceftaroline-Avibactam on the Normal Human Intestinal Microbiota.
Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteria; beta-Lactamase Inhibitors; beta-Lactams; Ceftaroline; Cephalosporins; Feces; Female; Gastrointestinal Microbiome; Healthy Volunteers; Humans; Male; Microbial Sensitivity Tests; Young Adult | 2015 |
13 other study(ies) available for beta-lactams and ppi-0903
| Article | Year |
|---|---|
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; United States | 2008 |
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactams; Binding, Competitive; Cefotaxime; Ceftaroline; Cephalosporins; Drug Resistance, Microbial; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillin G; Streptococcus pneumoniae | 2010 |
Rationale for eliminating Staphylococcus breakpoints for β-lactam agents other than penicillin, oxacillin or cefoxitin, and ceftaroline.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Cefoxitin; Ceftaroline; Cephalosporins; Humans; Microbial Sensitivity Tests; Oxacillin; Penicillins; Staphylococcal Infections; Staphylococcus; United States; United States Food and Drug Administration | 2014 |
Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Ceftaroline; Cephalosporins; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mutation | 2014 |
Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Ceftaroline; Ceftazidime; Cephalosporins; Escherichia coli; Humans; Microbial Sensitivity Tests | 2015 |
β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactams; Ceftaroline; Cephalosporins; Daptomycin; Enterococcus faecalis; Enterococcus faecium; Ertapenem; Microbial Sensitivity Tests; Vancomycin; Vancomycin-Resistant Enterococci | 2015 |
Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefazolin; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Ertapenem; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Nafcillin; Staphylococcal Infections; Vancomycin; Vancomycin-Resistant Enterococci | 2016 |
Whole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance.
Topics: Bacterial Proteins; beta-Lactams; Ceftaroline; Cephalosporins; Genome, Bacterial; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Models, Molecular; Mutation; Open Reading Frames; Penicillin-Binding Proteins; Promoter Regions, Genetic; Sequence Analysis, DNA | 2016 |
Susceptibility patterns of Staphylococcus aureus biofilms in diabetic foot infections.
Topics: Anti-Bacterial Agents; beta-Lactams; Biofilms; Ceftaroline; Cephalosporins; Diabetic Foot; Gentamicins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Polymerase Chain Reaction; Staphylococcal Infections; Staphylococcus aureus | 2016 |
β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA.
Topics: beta-Lactams; Cefazolin; Cefepime; Ceftaroline; Cephalosporins; Drug Synergism; Drug Therapy, Combination; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Nafcillin; Staphylococcal Infections; Vancomycin | 2018 |
Mechanistic Insights Into the Differential Efficacy of Daptomycin Plus β-Lactam Combinations Against Daptomycin-Resistant Enterococcus faecium.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; beta-Lactams; Ceftaroline; Cephalosporins; Daptomycin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Endocarditis, Bacterial; Enterococcus faecium; Ertapenem; Gram-Positive Bacterial Infections; Microbial Sensitivity Tests; Rats; Sequence Alignment; Transcriptome | 2020 |
Nonirritant concentrations and performance of ceftaroline skin tests in patients with an immediate β-lactam hypersensitivity.
Topics: Anti-Bacterial Agents; beta-Lactams; Ceftaroline; Cephalosporins; Drug Hypersensitivity; Humans; Hypersensitivity, Immediate; Skin Tests | 2021 |
Synergistic Combinations of FDA-Approved Drugs with Ceftobiprole against Methicillin-Resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; beta-Lactams; Ceftaroline; Cloxacillin; Floxacillin; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections | 2023 |